| Expanding global access to radiotherapy R Atun, DA Jaffray, MB Barton, F Bray, M Baumann, B Vikram, TP Hanna, ... The lancet oncology 16 (10), 1153-1186, 2015 | 984 | 2015 |
| Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the … JMM Raemaekers, MPE André, M Federico, T Girinsky, R Oumedaly, ... Journal of clinical oncology 32, 1188-1194, 2014 | 447 | 2014 |
| Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines T Girinsky, R van der Maazen, L Specht, B Aleman, P Poortmans, ... Radiotherapy and Oncology 79 (3), 270-277, 2006 | 442 | 2006 |
| Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project SM Bentzen, G Heeren, B Cottier, B Slotman, B Glimelius, Y Lievens, ... Radiotherapy and Oncology 75 (3), 355-365, 2005 | 302 | 2005 |
| Activity-based costing: a practical model for cost calculation in radiotherapy Y Lievens, W Van den Bogaert, K Kesteloot International Journal of Radiation Oncology* Biology* Physics 57 (2), 522-535, 2003 | 283 | 2003 |
| Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1 BJ Slotman, B Cottier, SM Bentzen, G Heeren, Y Lievens, ... Radiotherapy and oncology 75 (3), 349. E1-349. E6, 2005 | 243 | 2005 |
| Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey C Grau, N Defourny, J Malicki, P Dunscombe, JM Borras, M Coffey, ... Radiotherapy and Oncology 112 (2), 155-164, 2014 | 200 | 2014 |
| The optimal utilization proportion of external beam radiotherapy in European countries: an ESTRO-HERO analysis JM Borras, Y Lievens, P Dunscombe, M Coffey, J Malicki, J Corral, ... Radiotherapy and Oncology 116 (1), 38-44, 2015 | 187 | 2015 |
| How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis JM Borras, Y Lievens, M Barton, J Corral, J Ferlay, F Bray, C Grau Radiotherapy and Oncology 119 (1), 5-11, 2016 | 185 | 2016 |
| ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer U Nestle, D De Ruysscher, U Ricardi, X Geets, J Belderbos, C Pöttgen, ... Radiotherapy and oncology 127 (1), 1-5, 2018 | 179 | 2018 |
| Analysis of global radiotherapy needs and costs by geographic region and income level E Zubizarreta, J Van Dyk, Y Lievens Clinical Oncology 29 (2), 84-92, 2017 | 145 | 2017 |
| The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project JM Borras, M Barton, C Grau, J Corral, R Verhoeven, V Lemmens, ... Radiotherapy and Oncology 116 (1), 45-50, 2015 | 145 | 2015 |
| Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience N Lorent, P De Leyn, Y Lievens, E Verbeken, K Nackaerts, C Dooms, ... Annals of oncology 15 (11), 1645-1653, 2004 | 138 | 2004 |
| Comparison of Bayesian network and support vector machine models for two‐year survival prediction in lung cancer patients treated with radiotherapy K Jayasurya, G Fung, S Yu, C Dehing‐Oberije, D De Ruysscher, A Hope, ... Medical physics 37 (4), 1401-1407, 2010 | 132 | 2010 |
| Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey Y Lievens, N Defourny, M Coffey, JM Borras, P Dunscombe, B Slotman, ... Radiotherapy and oncology 112 (2), 178-186, 2014 | 127 | 2014 |
| Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? MK Thompson, P Poortmans, AJ Chalmers, C Faivre-Finn, E Hall, ... British journal of cancer, 2018 | 125 | 2018 |
| Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up RA Stahel, W Weder, Y Lievens, E Felip Annals of Oncology 21, v126-v128, 2010 | 124 | 2010 |
| The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines T Girinsky, L Specht, M Ghalibafian, V Edeline, G Bonniaud, ... Radiotherapy and Oncology 88 (2), 202-210, 2008 | 124 | 2008 |
| Development and external validation of prognostic model for 2-year survival of non–small-cell lung cancer patients treated with chemoradiotherapy C Dehing-Oberije, S Yu, D De Ruysscher, S Meersschout, K Van Beek, ... International Journal of Radiation Oncology* Biology* Physics 74 (2), 355-362, 2009 | 110 | 2009 |
| Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin’s lymphoma BMP Aleman, JMM Raemaekers, R Tomiŝiĉ, MHA Baaijens, R Bortolus, ... International Journal of Radiation Oncology* Biology* Physics 67 (1), 19-30, 2007 | 106 | 2007 |
